C. Bradley Hare

No New HIV Infections With Increasing Use of HIV Preexposure Prophylaxis in a Clinical Practice Setting: Figure 1.

Jonathan E. Volk, Julia L. Marcus, Tony Phengrasamy et al. · Clinical Infectious Diseases · 2015 · 492 citations · Full text

Public Health, Infectious Disease Control, Infectious Diseases +17

Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial

Kenneth H. Mayer, Jean‐Michel Molina, Melanie Thompson et al. · The Lancet · 2020 · 424 citations · Full text

Public Health, Pharmacology, Pharmacotherapy +17

Differences in HIV Burden and Immune Activation within the Gut of HIV‐Positive Patients Receiving Suppressive Antiretroviral Therapy

Steven A. Yukl, Sara Gianella, Elizabeth Sinclair et al. · The Journal of Infectious Diseases · 2010 · 292 citations · Full text

Life Sciences, Immunology, Infectious Diseases +17

Preexposure Prophylaxis for HIV Prevention in a Large Integrated Health Care System: Adherence, Renal Safety, and Discontinuation

Julia L. Marcus, Leo B. Hurley, C. Bradley Hare et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2016 · 289 citations · Full text

Public Health, Infectious Disease Control, Preventive Medicine +17

Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy

Steven A. Yukl, Amandeep K. Shergill, Kenneth R. McQuaid et al. · AIDS · 2010 · 234 citations

Medicine, Infectious Diseases, Pharmacology +17